Edgen Stock·Sep 20 2025, 10:21戻る
戻る
Intellia Therapeutics Gains on Progress in Hereditary Angioedema Trial
Edgen Stock·Sep 20 2025, 10:21
[1] Strength Seen in Intellia Therapeutics (NTLA): Can Its 29.8% Jump Turn into More Strength?[2] Intellia Therapeutics: Company Overview and Financial Analysis[3] Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema - GlobeNewswire